1. Home
  2. COP vs SNY Comparison

COP vs SNY Comparison

Compare COP & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ConocoPhillips

COP

ConocoPhillips

N/A

Current Price

$132.28

Market Cap

162.0B

Sector

Energy

ML Signal

N/A

Logo Sanofi ADS

SNY

Sanofi ADS

HOLD

Current Price

$45.91

Market Cap

104.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
COP
SNY
Founded
1917
1994
Country
United States
France
Employees
N/A
N/A
Industry
Integrated oil Companies
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
162.0B
104.5B
IPO Year
2005
2001

Fundamental Metrics

Financial Performance
Metric
COP
SNY
Price
$132.28
$45.91
Analyst Decision
Buy
Buy
Analyst Count
23
5
Target Price
$123.65
$58.00
AVG Volume (30 Days)
6.4M
3.0M
Earning Date
04-30-2026
04-23-2026
Dividend Yield
2.62%
3.47%
EPS Growth
N/A
N/A
EPS
5.00
N/A
Revenue
$58,944,000,000.00
N/A
Revenue This Year
$6.88
$3.49
Revenue Next Year
N/A
$6.10
P/E Ratio
$26.67
$6.14
Revenue Growth
7.67
N/A
52 Week Low
$85.59
$40.89
52 Week High
$135.88
$52.68

Technical Indicators

Market Signals
Indicator
COP
SNY
Relative Strength Index (RSI) 65.81 62.69
Support Level $113.24 $43.28
Resistance Level $135.87 $48.66
Average True Range (ATR) 3.05 0.52
MACD 0.76 0.23
Stochastic Oscillator 81.56 87.91

Price Performance

Historical Comparison
COP
SNY

About COP ConocoPhillips

ConocoPhillips is a US-based independent exploration and production firm. Its operations are primarily in Alaska and the Lower 48, with footprints in Canada, Europe, Asia-Pacific, the Middle East, and Africa. It also has substantial integrated liquefied natural gas production and marketing activities across geographies.

About SNY Sanofi ADS

Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.

Share on Social Networks: